Healthcare

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, a BMO survey suggests.

Second-quarter profit jumps 46% at Netflix, while a report says Union Pacific is in early-stage talks to buy smaller railroad rival Norfolk Southern.

The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after two teenage boys receiving the treatment died earlier this year.

President Donald Trump said on Wednesday that Coca-Cola had agreed to sweeten its signature soda with cane sugar in the U.S.

Lucid soars after announcing a self-driving partnership with Uber Technologies and Nuro, Taiwan Semiconductor Manufacturing reports a record profit in the second quarter, and PepsiCo’s adjusted earnings top forecasts.

Abbott Laboratories stock falls even as the company reports second-quarter sales that top expectations.

The health insurer now expects 2025 earnings of just $30 a share, citing ongoing and industry-wide impact of elevated cost trends in ACA and Medicaid.

Shares of the sleep-apnea treatment maker have gained 32% since Barron’s recommended them.

ASML falls sharply after issuing a growth warning, while Goldman Sachs, Morgan Stanley, and Bank of America post better-than-expected quarterly earnings.

The company reports adjusted earnings of $2.77 a share for the second quarter, beating analysts’ estimates of $2.68.

Shares have cratered since April, when the company slashed its financial guidance and posted earnings that missed expectations.

House deals a blow to “Crypto Week,” ASML warns on 2026 growth, a promising Chinese weight-loss drug, and more news to start your day.

Raymond James analyst Greg Peters says the slumping casualty-insurance sector may get a break from a less-stormy hurricane season.

Boeing shares rise as the accident of Air India flight 171 doesn’t appear to have anything to do with aircraft design or manufacturing, while MicroStrategy and crypto-related stocks jump as Bitcoin sets a record high.

The company, formerly part of Johnson & Johnson, says it is taking steps “to accelerate profitable growth.”

Life sciences firm Waters will take on $4 billion in debt, and issue 39.2% of its shares to Becton Dickinson shareholders.

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

Nvidia rises and pushes its market capitalization north of $4 trillion. It’s the first U.S. firm to reach and close above that level. Delta’s earnings beat analysts’ estimates.

Ultragenyx and partner Mereo BioPharma’s brittle bone disease trial will continue. Investors had wanted data good enough to end it early.

The deal is expected to close in the fourth quarter of 2025.

DexCom’s decision to pursue the Type 2 diabetes market wasn’t faulty. It was management’s execution of its strategy that caused the problem.

The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

The insurer says earnings pressure is expected to continue into the second half of the year.

The Republican megabill combined with new federal rules tightening eligibility will affect most people who use plans created by the Affordable Care Act.